ClinicalTrials.gg
RecruitingNCT07146165EndoTEMUpdated Mar 31, 2026

Clinical Evaluation of a New Platform for Bi-manual Endoscopic Resection in the Rectum and Sigma (EndoTEM)

An interventional study of EndoTEM resection platform and technique in Adenoma Colon Polyp and Adenoma Colon, sponsored by Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF). Recruiting at 3 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Polyps with a site in Germany — 4 open to participants now, 4 under way, 1 of them phase 3. Polyps · Germany.

Planned enrollment
13th of 13
30 · median 225
Started
2025
with 2 others
No phase
11 of 22
2 open now
Registered
22nd of 22
by date
Lead sponsor
1 of 22
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)

Among the 22 studies in Polyps with a site in Germany, this one is the 13th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2025, is one of 11 with no phase, and was the 22nd registered.

Polyps

312 studies on the registry are indexed under Polyps; 59 are open to participants now.

Browse Polyps studies →

Open to participants now

4 of the 22 studies in Polyps with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 34 Polyps studies recruiting now, 25 (74%) set no upper age limit and 6 (18%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Polyps with a site in Germany, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine whether the use of the EndoTEM system during the endoscopic removal of polyps in the distal colon is feasible and safe.

The main questions it aims to answer are:

  • Is the use of the EndoTEM system during the endoscopic removal of polyps in the distal colon feasible (i.e., does it enable complete resection of the polyp)?
  • Is the use of the EndoTEM system during the endoscopic removal of polyps in the distal colon safe?

Participants will:

  • be treated with the EndoTEM system during the endoscopic submucosal dissection of polyps in the distal colon.
  • answere questionnaires on fecal continence and quality of life before and after the intervention.
  • be treated following standard clinical procedures before, during and after the endoscopic removal.
03

Conditions studied

  • Adenoma Colon Polyp
  • Adenoma Colon

Browse trials for

Keywords

  • endoscopic submucosal dissection
  • endoscopic en bloc resection
  • EndoTEM system
  • endoscopic portsystem
  • ESD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Availability of written from the patient
  • Age > 18 years
  • Adenoma or early carcinoma > 2 cm in the rectum or distal sigmoid colon with indication for endoscopic en bloc resection using endoscopic submucosal dissection

Exclusion criteria

Exclusion Criteria:

  • not possible (e.g., language barrier)
  • Stenoses or fistulas in the anal region
  • Distance to the anocutaneous line ≤ 2 cm
  • Distance to the anocutaneous line > 20 cm
  • Individual medical assessment required for patients taking anticoagulant medication, in accordance with current ESGE guidelines
  • Pregnancy or breastfeeding
  • Vulnerable individuals
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    EndoTEM-System

    Utilization of the EndoTEM system in the performance of routine endoscopic en bloc resection using endoscopic submucosal dissection.

    Device: EndoTEM resection platform and technique

Interventions

  • DeviceEndoTEM resection platform and technique

    EndoTEM is a flexible transanally introduced port system that allows the insertion of a second instrument alongside the flexible endoscope. A curved rigid grasping instrument has been developed, with a 2 cm long tip that can be rotated and angled in all directions.

    Also known as: endoscopic portsystem

06

What researchers measure

Primary outcomes

  1. Technical success of the endoscopic resection

    Macroscopically complete resection.

    Time frame: From the endoscopic resection to the follow-up endoscopy after 6 months.

Secondary outcomes

  1. R0 resection rate

    Histological complete resection.

    Time frame: Assessed with a biopsy collected during the intervention.

  2. En bloc resection rate

    Endoscopic removal of the polyp in one intact piece, including any necessary surrounding tissue.

    Time frame: Assessed during the intervention.

  3. Duration of the procedure

    Time frame: From endoscope insertion until the end of procedure including supplementary and prophylactic interventions.

  4. Resection time

    Time frame: From start of the resection until detachment of the specimen.

  5. Resection speed

    Resected area per minute (mm²/min).

    Time frame: Assessed during the intervention.

  6. Periprocedural complications

    Time frame: Complications that occur during or immediately around the intervention (until 3-6 months post-intervention).

  7. Requirement for surgical intervention

    Time frame: During the endoscopic submucosal dissection.

  8. Rate of recurrence

    Time frame: Assessed during follow-up endoscopy 3-6 months post-intervention.

07

Study locations

1 of 3 sites recruiting
08

References and documents

Publications

  • Mueller J, Miedtke V, Kuellmer A et al. A novel endoscopic technique and device for bimanual rectosigmoidal ESD. Endoscopy 2023; 55(S02): 264 - 264. doi:10.1055/s-0043-1765725

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Aug 2028, 34 months after the start.

Of 68 non-industry interventional studies with no phase under Polyps, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 34 months is above that.

Counting every sponsor, half of 79 studies reached it within 23 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2025
First posted
Aug 28, 2025
StartActual
Oct 2, 2025
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2028
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07146165
Lead sponsor
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
Collaborators
Ovesco Endoscopy AG, Tuebingen Scientific Medical GmbH
Responsible party
Sponsor
First posted
Aug 28, 2025
Start date
Oct 2, 2025
Primary completion
Aug 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Mar 31, 2026

Study contacts

Arthur Schmidt, Prof. Dr. med.
principal investigator · Robert Bosch Krankenhaus GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion